NASDAQ · RLMD
Healthcare · Biotechnology
$4.43
Up+$0.06 (+1.37%)
Updated Sep 6, 2026, 8:09 AM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
RLMD closed at $4.43 after 20 trading sessions, down 2.42% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $4.35 | $4.44 | $4.32 | $4.43 | 675.56K |
| Sep 3, 2026 | $4.55 | $4.58 | $4.33 | $4.37 | 847.51K |
| Sep 2, 2026 | $4.54 | $4.5932 | $4.365 | $4.54 | 1.42M |
| Sep 1, 2026 | $4.31 | $4.51 | $4.31 | $4.46 | 944.06K |
| Aug 31, 2026 | $4.31 | $4.395 | $4.285 | $4.36 | 628.24K |
| Aug 28, 2026 | $4.51 | $4.53 | $4.32 | $4.33 | 678.36K |
| Aug 27, 2026 | $4.53 | $4.58 | $4.485 | $4.52 | 496.49K |
| Aug 26, 2026 | $4.57 | $4.60 | $4.46 | $4.55 | 476.69K |
| Aug 25, 2026 | $4.63 | $4.725 | $4.57 | $4.59 | 1.03M |
| Aug 24, 2026 | $4.64 | $4.64 | $4.375 | $4.58 | 935.75K |
| Aug 21, 2026 | $4.68 | $4.76 | $4.54 | $4.63 | 985.17K |
| Aug 20, 2026 | $4.74 | $4.79 | $4.55 | $4.64 | 1.03M |
| Aug 19, 2026 | $4.94 | $4.98 | $4.79 | $4.83 | 595.94K |
| Aug 18, 2026 | $4.75 | $4.86 | $4.71 | $4.85 | 751.7K |
| Aug 17, 2026 | $4.75 | $4.84 | $4.70 | $4.77 | 955.95K |
| Aug 14, 2026 | $4.74 | $4.835 | $4.68 | $4.80 | 925.43K |
| Aug 13, 2026 | $4.74 | $4.89 | $4.655 | $4.75 | 1.25M |
| Aug 12, 2026 | $4.52 | $4.81 | $4.51 | $4.72 | 1.66M |
| Aug 11, 2026 | $4.55 | $4.63 | $4.35 | $4.47 | 2.14M |
| Aug 10, 2026 | $4.91 | $4.9351 | $4.505 | $4.54 | 1.81M |
The latest Smart Investors Daily articles mentioning RLMD.
RLMD research
Company profile and research snapshot.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 18, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 24, 2026 | Piper Sandler | Overweight | — |
| Mar 20, 2026 | Mizuho | Outperform | — |
| Mar 2, 2026 | LUCID CAPITAL MARKETS | Buy | — |
| Jan 23, 2026 | Leerink Partners | Outperform | — |
No generated briefing is available yet.
Yahoo · Aug 7, 2026
Relmada Therapeutics (NASDAQ:RLMD) said it is prioritizing manufacturing activities for NDV-01, its sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, as it targets an investigational new drug application filing by the end of 2026. Chief
Yahoo · Aug 7, 2026
Relmada Therapeutics Inc (RLMD) reports robust NDVO1 efficacy and a solid cash runway, but manufacturing delays push IND filing to end of 2026.
SeekingAlpha · Aug 7, 2026
Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsJoyce LonerganSergio Traversa - CEO &...
Yahoo · Aug 6, 2026
Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational program upon IND clearance.Sepranolone IND filing expected by year-end 2026 and initiation of Phase 2 proof-of-concept study in Prader-Willi Syndrome upon IND clearance. Strengthened the leadership team with appointment of Bipin Dalmia as Chief Business Officer.Added to the Russell 2000® and Russell 3000® Indexes effective June 2
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RLMD.
